FDA approves JNJ's combination therapy for patients with a type of lung cancer

In this article:

March 1 (Reuters) - The FDA said on Friday it has approved Johnson & Johnson's therapy in combination with other chemotherapies for the first-line treatment of a type of lung cancer. (Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)

Advertisement